Read + Share
Lin L, Pan H, Li X, Zhao C, et al. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC
after progression on EGFR tyrosine kinase inhibitors. Lung Cancer 2022;166:98-106.
PMID: 35248866
|
 |
|
Lin L, Pan H, Li X, Zhao C, et al. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC
after progression on EGFR tyrosine kinase inhibitors. Lung Cancer 2022;166:98-106.
PMID: 35248866
|
|
|
|